Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer

ZOL did not improve DFS when combined with CT. However, the improvement of the pCR rate translated to survival outcomes in TN breast cancer. The short-term application of ZOL may not be sufficient to improve the outcome in postmenopausal patients.